131
Participants
Start Date
November 30, 2003
Primary Completion Date
July 31, 2008
Study Completion Date
July 31, 2008
GW572016 (lapatinib)
tyrosine kinase inhibitor
GSK Investigational Site, Nyack
GSK Investigational Site, Philadelphia
GSK Investigational Site, Washington D.C.
GSK Investigational Site, Durham
GSK Investigational Site, Gainsville
GSK Investigational Site, Jasper
GSK Investigational Site, Nashville
GSK Investigational Site, Cleveland
GSK Investigational Site, Elk Grove Village
GSK Investigational Site, Metairie
GSK Investigational Site, Houma
GSK Investigational Site, Houston
GSK Investigational Site, Corpus Christi
GSK Investigational Site, Santa Fe
GSK Investigational Site, Long Beach
GSK Investigational Site, La Jolla
GSK Investigational Site, Poway
GSK Investigational Site, Rancho Mirage
GSK Investigational Site, Portland
GSK Investigational Site, Greenbrae
GSK Investigational Site, Lebanon
GSK Investigational Site, New Brunswick
GSK Investigational Site, Chapel Hill
GSK Investigational Site, Calgary
GSK Investigational Site, Edmonton
GSK Investigational Site, Kingston
GSK Investigational Site, Kitchener
GSK Investigational Site, Ottawa
GSK Investigational Site, Toronto
GSK Investigational Site, Greenfield Park
GSK Investigational Site, Lévis
Lead Sponsor
GlaxoSmithKline
INDUSTRY